

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/519082
Applicant : RASI et al.
Filed : September 7, 2005
TC/A.U. : 1614
Examiner :
Confirmation No. : 6975

Docket No. : 2697-116
Customer No. : 6449




Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith information that the Office may wish to consider in examination of the subject application. Materials submitted for consideration are listed on the attached form PTO-1449.

Respectfully submitted,

By: 
George R. Repper
Attorney for Applicants
Registration No. 31,414
ROTHWELL, FIGG, ERNST & MANBECK, P.C.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202) 783-6040



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Complete if Known

Application Number	10/519082
Filing Date	September 7, 2005
First Named Inventor	RASI
Group Art Unit	1614
Examiner Name	
Confirmation No.	6975

Sheet

1

of

1

Attorney Docket Number

2697-116

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	1	BEPLER, G., <i>Thymosin alpha-1 as adjunct for conventional therapy of malignant tumors: a review</i> , Cancer Investigation (1994) 12:5, 491-496	
	2	GOLDSTEIN, A., <i>Clinical applications of thymosin alpha-1</i> , Cancer Investigation (1994) 12:5, 545-547	
	3	RASI, G., et al., <i>Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats</i> , Int. J. Cancer (1994) 57:701-705	
	4	SILECCHIA, G., et al., <i>Efficacy of repeated cycles of chemo-immunotherapy with thymosin a1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery</i> , Cancer Immunol Immunother (1999) 48:172-178	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.